MedTrace Logo

Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery

NCT03436836 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-05-30

No results posted yet for this study

Summary

Nalbuphine has been used as an adjuvant to bupivacaine in intrathecal, epidural, caudal anesthesia and peripheral nerve blocks showing an increase in the efficacy and the duration of postoperative analgesia.The aim of this study is evaluation of the effect of nalbuphine when used as an adjuvant to a local anesthetic mixture in peribulbar block undergoing cataract surgery

Conditions

  • Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery

Interventions

DRUG

Nalbuphine

Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study. After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery

DRUG

lidocaine, bupivacaine, hyaluronidase , saline

lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).

DRUG

lidocaine, bupivacaine , hyaluronidase

2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)

Sponsors & Collaborators

  • Mohamed, Ahmed A., M.D.

    collaborator INDIV

  • Nadia Yossif Helmy

    collaborator UNKNOWN

  • Ahmed Elbadawy Mahmoud

    collaborator UNKNOWN

  • Abdelhamid, Bassant Mohamed, M.D.

    collaborator INDIV

  • Atef Kamel Salama

    collaborator UNKNOWN

  • Mostafa Abdalwahab Elberry

    collaborator UNKNOWN

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-14
Primary Completion
2018-02-20
Completion
2018-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03436836 on ClinicalTrials.gov